Kinetics and Mechanism of Autoprocessing of Human Immunodeficiency Virus Type 1 Protease from an Analog of the Gag-Pol Polyprotein

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1994 Aug 16

PMID 8058744

Citations 45

Authors

J M Louis

N T Nashed

K D Parris

A R Kimmel

D M Jerina

Affiliations

Soon will be listed here.

Abstract

Upon renaturation, the polyprotein MBP-delta TF-Protease-delta Pol, consisting of HIV-1 protease and short native sequences from the trans-frame protein (delta TF) and the polymerase (delta Pol) fused to the maltose-binding protein (MBP) of Escherichia coli, undergoes autoprocessing to produce the mature protease in two steps. The initial step corresponds to cleavage of the N-terminal sequence to release the protein intermediate Protease-delta Pol, which has enzymatic activity comparable to that of the mature enzyme. Subsequently, the mature enzyme is formed by a slower cleavage at the C terminus. The rate of increase in enzymatic activity is identical to that of the appearance of MBP-delta TF and the disappearance of the MBP-delta TF-Protease-delta Pol. Initial rates are linearly dependent on the protein concentration, indicating that the N-terminal cleavage is first-order in protein concentration. The reaction is competitively inhibited by pepstatin A and has a pH rate profile similar to that of the mature enzyme. These results and molecular modeling studies are discussed in terms of a mechanism in which a dimeric full-length fusion protein must form prior to rate-limiting intramolecular cleavage of the N-terminal sequence that leads to an increase in enzymatic activity.

Citing Articles

Interplay between protease and reverse transcriptase dimerization in a model HIV-1 polyprotein.

Chagas B, Zhou X, Guerrero M, Ilina T, Ishima R Protein Sci. 2024; 33(7):e5080.

PMID: 38896002 PMC: 11187873. DOI: 10.1002/pro.5080.

Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors.

Aniana A, Nashed N, Ghirlando R, Coates L, Kneller D, Kovalevsky A Commun Biol. 2023; 6(1):1159.

PMID: 37957287 PMC: 10643566. DOI: 10.1038/s42003-023-05469-8.

Kinetics of Bovine leukemia virus aspartic protease reveals its dimerization and conformational change.

Flo M, Carrion F, Olivero-Deibe N, Bianchi S, Portela M, Rammauro F PLoS One. 2022; 17(7):e0271671.

PMID: 35867649 PMC: 9307154. DOI: 10.1371/journal.pone.0271671.

Multimodal Functionalities of HIV-1 Integrase.

Engelman A, Kvaratskhelia M Viruses. 2022; 14(5).

PMID: 35632668 PMC: 9144474. DOI: 10.3390/v14050926.

Biochemical characterization of Ty1 retrotransposon protease.

Gazda L, Joone Matuz K, Nagy T, Motyan J, Tozser J PLoS One. 2020; 15(1):e0227062.

PMID: 31917798 PMC: 6952103. DOI: 10.1371/journal.pone.0227062.

References

Marciniszyn Jr J, Huang J, Hartsuck J, Tang J . Mechanism of intramolecular activation of pepsinogen. Evidence for an intermediate delta and the involvement of the active site of pepsin in the intramolecular activation of pepsinogen. J Biol Chem. 1976; 251(22):7095-102. View

Lin X, Lin Y, Koelsch G, Gustchina A, Wlodawer A, Tang J . Enzymic activities of two-chain pepsinogen, two-chain pepsin, and the amino-terminal lobe of pepsinogen. J Biol Chem. 1992; 267(24):17257-63. View

Rich D . Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor. J Med Chem. 1985; 28(3):263-73. DOI: 10.1021/jm00381a001. View

SATOW Y, Cohen G, Padlan E, Davies D . Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol. 1986; 190(4):593-604. DOI: 10.1016/0022-2836(86)90245-7. View

Kohl N, Emini E, Schleif W, Davis L, Heimbach J, Dixon R . Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988; 85(13):4686-90. PMC: 280500. DOI: 10.1073/pnas.85.13.4686. View

Darke P, NUTT R, Brady S, Garsky V, Ciccarone T, Leu C . HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun. 1988; 156(1):297-303. DOI: 10.1016/s0006-291x(88)80839-8. View

Navia M, Fitzgerald P, McKeever B, Leu C, Heimbach J, Herber W . Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989; 337(6208):615-20. DOI: 10.1038/337615a0. View

Skalka A . Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell. 1989; 56(6):911-3. DOI: 10.1016/0092-8674(89)90621-1. View

Wlodawer A, Miller M, Jaskolski M, Sathyanarayana B, Baldwin E, Weber I . Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989; 245(4918):616-21. DOI: 10.1126/science.2548279. View

10.

Nashed N, Louis J, Sayer J, Wondrak E, Mora P, Oroszlan S . Continuous spectrophotometric assay for retroviral proteases of HIV-1 and AMV. Biochem Biophys Res Commun. 1989; 163(2):1079-85. DOI: 10.1016/0006-291x(89)92331-0. View

11.

Kay J, Dunn B . Viral proteinases: weakness in strength. Biochim Biophys Acta. 1990; 1048(1):1-18. DOI: 10.1016/0167-4781(90)90015-t. View

12.

Richards A, Phylip L, Farmerie W, Scarborough P, Alvarez A, Dunn B . Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J Biol Chem. 1990; 265(14):7733-6. View

13.

Billich A, Hammerschmid F, Winkler G . Purification, assay and kinetic features of HIV-1 proteinase. Biol Chem Hoppe Seyler. 1990; 371(3):265-72. View

14.

Fitzgerald P, McKeever B, VanMiddlesworth J, Springer J, Heimbach J, Leu C . Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem. 1990; 265(24):14209-19. View

15.

Spurlino J, Lu G, Quiocho F . The 2.3-A resolution structure of the maltose- or maltodextrin-binding protein, a primary receptor of bacterial active transport and chemotaxis. J Biol Chem. 1991; 266(8):5202-19. DOI: 10.2210/pdb1mbp/pdb. View

16.

Krausslich H . Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci U S A. 1991; 88(8):3213-7. PMC: 51416. DOI: 10.1073/pnas.88.8.3213. View

17.

Louis J, McDonald R, Nashed N, Wondrak E, Jerina D, Oroszlan S . Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. Eur J Biochem. 1991; 199(2):361-9. DOI: 10.1111/j.1432-1033.1991.tb16132.x. View

18.

Fitzgerald P, Springer J . Structure and function of retroviral proteases. Annu Rev Biophys Biophys Chem. 1991; 20:299-320. DOI: 10.1146/annurev.bb.20.060191.001503. View

19.

Broadhurst A, Roberts N, Ritchie A, Handa B, Kay C . Assay of HIV-1 proteinase: a colorimetric method using small peptide substrates. Anal Biochem. 1991; 193(2):280-6. DOI: 10.1016/0003-2697(91)90022-l. View

20.

Hyland L, Tomaszek Jr T, Meek T . Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry. 1991; 30(34):8454-63. DOI: 10.1021/bi00098a024. View